Investigational drug · Phase 3
PLG0206
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prosthetic-joint Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PLG0206"
First trial start
2026
Feb 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PLG0206", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prosthetic-joint Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "PLG0206" as an intervention, largest first.
- Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee ArthroplastyPivotal-lookingRecruiting
PeptilogicsIndustry
NCT07214311 · 240 participants (planned) · Start Feb 3, 2026 · Primary completion Sep 2028
Drug: PLG0206; Placebo · For: Prosthetic-joint Infection
Sites: Pensacola, Florida; Sarasota, Florida; Tamarac, Florida · 24 sites in all
PeptilogicsIndustry
NCT05137314 · 14 participants · Start Mar 31, 2022 · Primary completion Mar 19, 2024
Drug: PLG0206 · For: Joint Infection
Sites: Palo Alto, California; Sarasota, Florida; Baltimore, Maryland · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Peptide Therapeutics in Orthopaedics: Current Evidence and Future Directions.
Urish KL, Osifo SE, Steckbeck JD · J Bone Joint Surg Am 2026
- Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials.
Kontogiannis DS, Romanos LT, Tzvetanova ID, et al. · Expert Opin Investig Drugs 2025
- Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials.
Romanos LT, Kontogiannis DS, Tsiampali C, et al. · Expert Opin Investig Drugs 2025
- Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.
Huang DB, Brothers KM, Mandell JB, et al. · PLoS One 2022
- Evolved resistance to a novel cationic peptide antibiotic requires high mutation supply.
Santos-Lopez A, Fritz MJ, Lombardo JB, et al. · Evol Med Public Health 2022
- A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.
Huang D, Dobbins D, Ghahramani P, et al. · Antimicrob Agents Chemother 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.